Did You Know...
...that after Parker Brothers executives turned down the game of Monopoly because it had "52 fundamental errors" (including taking too long to play), a copy of the game wound up in the home of the company president who stayed up until 1 a.m. to finish playing it? He was so impressed by the game that the next day he wrote to inventor Charles Darrow and offered to buy it!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6756491 | Steroid-activated nuclear receptors and uses therefor In accordance with the present invention, there is provided an example of a novel class of nuclear receptor(s), termed the steroid X receptor (SXR). SXR is expressed almost exclusively in the liver, the primary site of xenobiotic and steroid catabolism. Unlike class... | 06/29/2004 |
| 6544727 | Methods and devices for the removal of psoralens from blood products Methods and devices for the removal of psoralens and psoralen photoproducts from blood products are described. The methods include contacting a psoralen- and irradiation-treated blood product with a resin capable of adsorbing psoralens and psoralen photop... | 04/08/2003 |
| 6346394 | Recombinant thermostable enzyme which releases trehalose from non-reducing saccharide Disclosed is a recombinant thermostable enzyme which has a molecular weight of about 54,000-64,000 daltons and a pI of about 5.6-6.6, and releases trehalose from non-reducing saccharides having a trehalose structure as an end unit and a degree of glucose ... | 02/12/2002 |
| 6316186 | Binding assay using binding agents with tail groups The present invention discloses methods and kits for the determination of the concentration of one or more analytes in a liquid sample using capture agents immobilized on a solid support and binding agents for binding the analyte(s), the binding agents ha... | 11/13/2001 |
| 6309979 | Methods for reducing plasma-induced charging damage A method in a high density plasma chamber for protecting a semiconductor substrate from charging damage from plasma-induced current through the substrate while etching through a selected portion of a conductive layer above the substrate. The method includ... | 10/30/2001 |
| 6300064 | Protein/(poly)peptide libraries The present invention relates to synthetic DNA sequences which encode one or more collections of homologous proteins/(poly)peptides, and methods for generating and applying libraries of these DNA sequences. In particular, the invention relates to the prep... | 10/09/2001 |
| 6300104 | Secretory immunoglobulin produced by single cells and methods for making and using same Disclosed is a method of producing secretory Ig molecules. The method comprises transfecting a cell producing an Ig with a polynucleotide encoding an SC to fonn SC transfected Ig producing cells. Secretory Ig molecules, such as secretory IgA, can be used ... | 10/09/2001 |
| 6287620 | Flavor enhancing methods -keto acids and certain precursors and derivatives thereof, particularly those selected from the group which consists of glyoxylic acid, 2-oxo-propanoic acid, 2-oxo-butanoic acid, 3-methyl-2-oxo butanoic acid, 3-methyl-2-oxo pentanoic acid, 4-methy... | 09/11/2001 |
| 6284367 | Process for the preparation of nonwoven water blocking tapes and their use in cable manufacture A process for the manufacture of a nonwoven water blocking tape for use in cable manufacture, which process comprises the steps of: (i) forming a coating of an aqueous solution of a water soluble polymer containing anionic groups and a multivalent ionic crossl... | 09/04/2001 |
| 6280974 | Recombinant feline coronavirus S proteins The present invention provides polynucleotide molecules encoding portions of the S protein from feline infectious peritonitis virus (FIPV). The present invention further provides polynucleotide molecules encoding the entire S protein or portions thereof f... | 08/28/2001 |
| 6277631 | Recombinant proteins with the immunoreactivity of hepatitis B virus e antigen (HBeAg), a process for the preparation thereof and the use thereof in immunoassays and vaccines Recombinant yeast expression vectors with the features indicated in the patent claims are described. These recombinant yeast expression vectors can be used for the preparation of HBeAg in yeast host organisms. Appropriate expression systems, transformed h... | 08/21/2001 |
| 6274148 | Hepatitis C virus asialoglycoproteins Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which ar... | 08/14/2001 |
| 6270800 | Aqueous solvent based encapsulation of a bovine herpes virus type-1 subunit vaccine A microencapsulated subunit component from bovine herpes virus-1 (BHV-1) is disclosed. Vaccines, kits, and methods for using the same to vaccinate a member of a bovine species are also disclosed.... | 08/07/2001 |
| 6270769 | Induction of cytotoxic T-lymphocyte responses Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing a... | 08/07/2001 |
| 6261569 | Retro-, inverso- and retro-inverso synthetic peptide analogues Synthetic peptide antigen analogues of native peptide antigens with partial or complete retro, inverso or retro-inverso modifications are provided. When administered as an immunogen to an immunocompetent host the synthetic peptide antigen analogues induce... | 07/17/2001 |
| 6245503 | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E1/E2 characterized in that upon lysing the transformed host cells to isolate the recom... | 06/12/2001 |
| 6232099 | Method of producing a chimeric protein A method of producing a chimeric protein from ie a plant virus coding for such a protein. The method allows the production of large (ie 25 kDa) proteins which assemble with the virus in infected host cells and are arranged on the outer surface of chimeric... | 05/15/2001 |
| 6232459 | Synaptojanin isoform The invention provides a human synaptojanin isoform (NSYN-1) and polynucleotides which identify and encode NSYN-1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for tr... | 05/15/2001 |
| 6217858 | Pharmaceutical composition for treating hepatitis B virus (HBV) infection The invention provides a pharmaceutical composition for the treatment of hepatitis B virus (HBV) infection, comprising an amount of a soluble active agent which interacts with at least one of the binding sites between hIL6 and pS1 and between hIL6 and hep... | 04/17/2001 |
| 6214583 | HCV genomic sequences for diagnostics and therapeutics The present application features nucleic acid, peptide and antibody compositions relating to genotypes of hepatitis C virus and methods of using such compositions for diagnostic and therapeutic purposes.... | 04/10/2001 |
| 6210675 | PT-NANB hepatitis polypeptides The invention relates to post-transfusional non-A non-B hepatitis viral polypeptide, DNA sequences encoding such viral polypeptide, expression vectors containing such DNA sequences, and hosts transformed by such expression vectors. The invention also rela... | 04/03/2001 |
| 6210719 | Yogurt flavor composition Flavor composition suitable for imparting a yogurt flavor to a food product and obtained by fermentation, characterised by a flavor so concentrated that the composition should be diluted at least 2 times, preferably at least 10 times, more preferably at l... | 04/03/2001 |
| 6200666 | Thermal transfer compositions, articles, and graphic articles made with same Thermal transfer articles of the invention comprising a carrier, optionally a release layer, a color layer releasably adhered thereto, and optionally an adherence layer on the bottom side of the color layer. Also graphic imaging compositions and methods f... | 03/13/2001 |
| 6197325 | Supplemented and unsupplemented tissue sealants, methods of their production and use This invention provides methods for the localized delivery of supplemented tissue sealants, wherein the supplemented tissue sealants comprise at least one composition which is selected from one or more antibodies, analgesics, anticoagulants, anti-inflamma... | 03/06/2001 |
| 6197311 | Induction of cytotoxic T-lymphocyte responses Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing a... | 03/06/2001 |
| 6194210 | Hepatitis A virus culture process A microcarrier based process to produce viral vaccines, of which one example is hepatitis A virus (HAV), is composed of an aggregated microcarrier system of glass coated polystyrene microcarriers and MRC-5 cells which creates a stable environment for the ... | 02/27/2001 |
| 6194017 | Dough punch and method of use An apparatus and method easily and quickly produce multiple holes in a dough layer. An apparatus according to the invention includes a top portion, a number of pins supported by the top portion in a fixed pattern, and a base portion having a number of hol... | 02/27/2001 |
| 6183754 | Anticytomegalovirus monoclonal antibodies and processes for the in vitro diagnosis of infections by human cytomegaloviruses and a protein-kinase inducible by cytomegaloviruses and recognizable by aforesaid monoclonal antibodies The invention relates to a process for in vitro diagnosis of an infection by human cytomegaloviruses. The process consists of contacting cells, possibly carrying the infection, with a monoclonal antibody reacting with a polypeptide of molecular weight 68,... | 02/06/2001 |
| 6184414 | Process for producing ammonium-2-hydroxy-4-(methylthio)-butyrate, mixtures containing the same in liquid form and their use Process for producing ammonium-2-hydroxy-4-(methylthio)-butyrate, mixtures containing the same in liquid form and their use. In order to produce ammonium-2-hydroxy-4-methylthio-n-butyrate and mixtures containing the same with a remarkable fluidity and a v... | 02/06/2001 |
| 6180102 | Monoclonal antibody to human Mx protein MxA This invention provides a monoclonal antibody which recognizes an epitope corresponding to amino acids 10 to 220, amino acids 221 to 297, or amino acids 469 to 662, counting from the N-terminus of a human Mx protein MxA, and specifically reacts with the h... | 01/30/2001 |
| 6177241 | Use of peptides to improve specificity of an immunoassay for the detection of cytomegalovirus specific IgM antibody This invention provides a method, a reagent, and a kit for detecting herpesvirus-specific IgM antibodies indicative of recent infection while preventing detection of low levels of herpesvirus-specific IgM antibodies present in individuals of low risk. The... | 01/23/2001 |
| 6172189 | Hepatitis C assay utilizing recombinant antigens The present invention provides unique recombinant antigens representing distinct antigenic regions of the Hepatitis C Virus (HCV) genome which can be used as reagents for the detection of antibodies and antigen in body fluids from individuals exposed to H... | 01/09/2001 |
| 6171782 | Antibody compositions to HCV and uses thereof A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infe... | 01/09/2001 |
| 6162620 | Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor HCMV glycoproteins B and H have been identified. The gB protein is encoded by DNA in the HindIII F fragment of the HCMV genome lying between 1378 and 4095 bases from the F/D boundary. The gH protein is encoded by DNA in the HindIII L fragment lying betwee... | 12/19/2000 |
| 6159481 | Sweat resistant sunblock and antioxidant composition A sweat resistant sunblock and antioxidant composition for protection against a broad spectrum of radiation. The composition contains micronized and ultramicronized titanium particles, micronized dermatologically acceptable metal oxides, micronized talc, ... | 12/12/2000 |
| 6153378 | Diagnosis of, and vaccination against, a positive stranded RNA virus using an isolated, unprocessed polypeptide encoded by a substantially complete genome of such virus The unprocessed polyprotein initially translated from the genome of a positive-stranded RNA virus contains epitopic configurations that are not retained in the processed proteins. The structural protein region, in particular, loses an epitopic configurati... | 11/28/2000 |
| 6150134 | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolat... | 11/21/2000 |
| 6146629 | Human monoclonal antibody against Hepatitis B virus surface antigen (HBVsAg) Disclosed is a hybridoma cell line which produces human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as antibodies produced by the cell line. Also disclosed are various uses of said antibodies in the prevention ... | 11/14/2000 |
| 6129922 | Methods for adjuvant free hepatitis A virus vaccination The invention provides the use of Hepatitis A virus capsid, or a mucosally immunogenic fragment or epitope thereof, for the manufacture of a mucosal vaccine composition for administration to a mucosal surface of a patient to induce production of serum Imm... | 10/10/2000 |
| 6129921 | Viral ribonucleocapsid as an immunological enhancer Methods of enhancing an antigen-induced immune response through use of a ribonucleocapsid complex are provided. Composition containing a ribonucleocapsid complex and an antigen which are capable of enhancing the immune response to the antigen are also pro... | 10/10/2000 |
